Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
20.59
+2.33 (12.76%)
At close: Apr 23, 2024, 4:00 PM
21.00
+0.41 (1.99%)
Pre-market: Apr 24, 2024, 4:00 AM EDT
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Cartesian Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 22, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Dr. Carsten Brunn Ph.D. |
Contact Details
Address: 65 Grove Street Watertown, Massachusetts 02472 United States | |
| Phone | 617-923-1400 |
| Website | selectabio.com |
Stock Details
| Ticker Symbol | RNAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453687 |
| CUSIP Number | 816212104 |
| ISIN Number | US8162123025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Director |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Operating Officer |
| Yi Zhang Ph.D. | Senior Director of Technology |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |